Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Evista Gains Breast Cancer Risk Reduction Claim But Adds Black Box Warning

Executive Summary

FDA's approval of Lilly's osteoporosis drug Evista for two preventative cancer treatment indications expands the drug's market into the oncology field, while placing it at odds with competing osteoporosis products because of new risk labeling

You may also be interested in...



GSK Temporarily Pulls sNDA For Avodart

GSK has temporarily pulled its supplemental application for Avodart for reducing the risk of prostate cancer, in order to update the data in the sNDA.

Pfizer Ready For Fablyn Vs. Evista Match, But FDA May Not Play Along

The long-term data from Pfizer's PEARL study are the firm's best bet for eking out a competitive distinction for its osteoporosis drug Fablyn against Lilly's Evista. FDA, however, seems less inclined to put those findings in labeling, particularly the breast cancer data

Pfizer Ready For Fablyn Vs. Evista Match, But FDA May Not Play Along

The long-term data from Pfizer's PEARL study are the firm's best bet for eking out a competitive distinction for its osteoporosis drug Fablyn against Lilly's Evista. FDA, however, seems less inclined to put those findings in labeling, particularly the breast cancer data

Related Content

UsernamePublicRestriction

Register

PS048816

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel